A PYMNTS Company

US: Class status upheld for Nexium pay-for-delay suit

By  |  January 26, 2015

Union health funds alleging that AstraZeneca paid generic drugmakers not to challenge its Nexium patents were properly certified as a class, the First Circuit ruled on Monday.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    According to reports, while the jury found that AstraZeneca had made unjustified payments to Ranbaxy to delay the release of a generic form of a competitive drug, the jury said those payments were not unreasonably anticompetitive because no competing Union health funds alleging that AstraZeneca paid generic drugmakers not to challenge its Nexium patents were properly certified as a class, the 1st Circuit ruled.

    The deal has kept any generic substitute for Nexium from reaching the market even though AstraZeneca’s patents expired in May 2014.

    The First Circuit affirmed class-action status for the case last week, despite claims that the lack of a generic alternative has not injured all class members.

    Full Content: Courthouse News Service

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.